Form D To Observe: Promentis Pharmaceuticals $8.79 million Fundraising. Daniel Lawton Submitted Oct 5 form D

Pharmaceuticals Promentis Pharmaceuticals, Inc. - Daniel Lawton

Promentis Pharmaceuticals Financing

Promentis Pharmaceuticals, Inc., Corporation just released form D announcing $8.79 million equity financing. This is a new filing. Promentis Pharmaceuticals was able to finance itself with $8.79 million. That is 100.00% of the fundraising offer. The total fundraising amount was $8.79 million. The private financing document was filed on 2016-10-05. The reason for the financing was: Proceeds are used for research and development and general corporate purposes. The executive officers and certain directors will receive compensation from the Issuer’s investment proceeds..

Promentis Pharmaceuticals is based in Wisconsin. The company’s business is Pharmaceuticals. The SEC form was signed by Daniel Lawton President. The company was incorporated more than five years ago. The filler’s address is: 826 N. Plankinton Ave., Ste. 400, Milwaukee, Wi, Wisconsin, 53203. Daniel Lawton is the related person in the form and it has address: 826 North Plankinton Avenue, Suite 400, Milwaukee, Wi, Wisconsin, 53203. Link to Promentis Pharmaceuticals Filing: 000147099416000001.

Analysis of Promentis Pharmaceuticals Offering

On average, startups in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Promentis Pharmaceuticals sold 100.00% of the offering. Could this mean that the trust in Promentis Pharmaceuticals is high? The average investment offering size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 1,480.47% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this offering was set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Promentis Pharmaceuticals Also

The Form D signed by Daniel Lawton might help Promentis Pharmaceuticals, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment